The true potential of cytokine therapies in cancer treatment is limited by the inability to
deliver optimal concentrations into tumor sites due to dose-limiting systemic toxicities. To
maximize the efficacy of cytokine therapy, recombinant antibody–cytokine fusion proteins
have been constructed by a number of groups to harness the tumor-targeting ability of
monoclonal antibodies. The aim is to guide cytokines specifically to tumor sites where they
might stimulate more optimal anti-tumor immune responses while avoiding the systemic …